- Home
- CYRX vs YMAB Comparison
CYRX vs YMAB Comparison
Compare CYRX & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYRX
- YMAB
- Stock Information
- Founded
- CYRX 1999
- YMAB 2015
- Country
- CYRX United States
- YMAB United States
- Employees
- CYRX N/A
- YMAB N/A
- Industry
- CYRX Biotechnology: Pharmaceutical Preparations
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- CYRX Health Care
- YMAB Health Care
- Exchange
- CYRX Nasdaq
- YMAB Nasdaq
- Market Cap
- CYRX 438.7M
- YMAB 386.7M
- IPO Year
- CYRX N/A
- YMAB 2018
- Fundamental
- Price
- CYRX $8.99
- YMAB $8.61
- Analyst Decision
- CYRX Strong Buy
- YMAB Buy
- Analyst Count
- CYRX 10
- YMAB 10
- Target Price
- CYRX $11.70
- YMAB $13.91
- AVG Volume (30 Days)
- CYRX 578.8K
- YMAB 874.6K
- Earning Date
- CYRX 11-06-2025
- YMAB 11-07-2025
- Dividend Yield
- CYRX N/A
- YMAB N/A
- EPS Growth
- CYRX N/A
- YMAB N/A
- EPS
- CYRX 1.35
- YMAB N/A
- Revenue
- CYRX $237,879,000.00
- YMAB $85,385,000.00
- Revenue This Year
- CYRX N/A
- YMAB N/A
- Revenue Next Year
- CYRX $9.08
- YMAB $13.97
- P/E Ratio
- CYRX $6.66
- YMAB N/A
- Revenue Growth
- CYRX 24.93
- YMAB N/A
- 52 Week Low
- CYRX $4.58
- YMAB $3.55
- 52 Week High
- CYRX $10.46
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- CYRX 51.87
- YMAB 81.21
- Support Level
- CYRX $8.53
- YMAB $8.50
- Resistance Level
- CYRX $10.46
- YMAB $8.56
- Average True Range (ATR)
- CYRX 0.57
- YMAB 0.02
- MACD
- CYRX -0.09
- YMAB -0.13
- Stochastic Oscillator
- CYRX 36.91
- YMAB 100.00
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.